login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
Emmaus Life Sciences Inc. (EMMA) Stock News
NASDAQ:EMMA - Nasdaq -
2.77
-1.72 (-38.31%)
After market: 2.73
-0.04 (-1.44%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
EMMA Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements
3 months ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Reports 2024 Financial Results
6 months ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia
10 months ago - By: Benzinga
- Mentions:
WYY
PMN
ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying
a year ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Reports Delayed Filing of Annual Report
a year ago - By: Benzinga
- Mentions:
GEG
ETST
Great Elm Group And 2 Other Stocks Under $2 Insiders Are Buying
2 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Reports Management Changes
2 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Provides Interim Shipment Data
3 years ago - By: Emmaus Life Sciences, Inc.
Dr. Niihara Meets with Local Indian Governor
a year ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences recibe la autorización de comercialización para Puerto Rico
a year ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico
2 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Reports Q3 2023 Financial Results
2 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Reports Q2 2023 Financial Results
3 years ago - By: Emmaus Life Sciences, Inc.
Endari® Receives Kuwaiti Marketing Authorization
2 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman
2 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA
2 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update
2 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update
3 years ago - By: Emmaus Life Sciences, Inc.
Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari®
3 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public Health
3 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update
3 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Announces Collaboration with Kier (Junior) Spates to Share Personal Experience with Sickle Cell Disease and Endari®
3 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update
3 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Announces Engagement of Strategic Business Relations and Professional Services Advisor
3 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update
3 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences to Present at Investor Conferences in May
3 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update
3 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari®
3 years ago - By: Emmaus Life Sciences, Inc.
Emmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology
Please enable JavaScript to continue using this application.